Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Neurosense Therapeutics Ltd. ( (NRSN) ) has issued an announcement.
NeuroSense Therapeutics announced receiving positive feedback from the FDA regarding the design of its Phase 3 study for PrimeC, a treatment for ALS. This positive feedback is a significant milestone, enabling the company to proceed with plans to commence a pivotal study in mid-2025. This development aligns with the company’s strategy to provide innovative solutions for ALS patients and could potentially strengthen its position in the biotechnology industry.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease. The company aims to address significant unmet medical needs with limited therapeutic options by developing combined therapies targeting multiple pathways associated with these diseases.
YTD Price Performance: 30.77%
Average Trading Volume: 187,898
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $21.12M
See more data about NRSN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue